Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  McCormick, Liam M ^a   Heck, Patrick M ^a   Ring, Liam S ^a   Kydd, Anna C ^a   Clarke, Sophie J ^a   Hoole, Stephen P ^a   Dutka, David P ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Coronary disease; Diabetes mellitus; Glucagon like peptide; Hyperglycemia; Stress echocardiography

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOBUTAMINE; FATTY ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; LONG ACTING DRUG; METFORMIN; NICORANDIL; NITRATE; SULFONYLUREA; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; GLUCOSE BLOOD LEVEL; INCRETIN; PEPTIDE FRAGMENT;

AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG MECHANISM; FEMALE; FUNCTIONAL ASSESSMENT; HEART CONTRACTION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; MALE; MITRAL ANNULAR SYSTOLIC VELOCITY; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PEAK SYSTOLIC VELOCITY; PHARMACOLOGIC STRESS TESTING; PROTEIN FUNCTION; STEADY STATE; STRESS ECHOCARDIOGRAPHY; STRESS STRAIN RELATIONSHIP; TISSUE DOPPLER IMAGING; BIOMECHANICS; BLOOD; CLINICAL TRIAL; COLOR DOPPLER ECHOCARDIOGRAPHY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREVENTION AND CONTROL;

AGED; BIOMARKERS; BIOMECHANICAL PHENOMENA; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ECHOCARDIOGRAPHY, STRESS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; INCRETINS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PEPTIDE FRAGMENTS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84938595638     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0259-3     Document Type: Article

References (43)

1. Capes SE, Hunt D, Malmberg K, Gerstein HC (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773-778
2. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T et al (2008) Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, physical activity, and metabolism. Circulation 117:1610-1619
3. Opie LH (2008) Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation 117:2172-2177
4. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283-1297
5. Zhao YT, Weng CL, Chen ML, Li KB, Ge YG, Lin XM et al (2010) Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials. Heart 96:1622-1626
6. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr et al (2014) 2014 AHA/ACC Guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64:2645-2687
7. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA et al (2013) ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013(127):e362-e425
8. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439
9. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D et al (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293:437-446
10. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962-965
11. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB et al (2012) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33:1491-1499
12. Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE et al (2011) A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 4:266-272
13. Read PA, Khan FZ, Dutka DP (2012) Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98:408-413
14. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP (2010) DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 3:195-201
15. McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP et al (2014) Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circulation Cardiovascu Imaging. 7:274-281
16. McCormick LM, Hoole SP, White PA, Read PA, Axell RG, Clarke SJ et al (2015) Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc Interv. 8:292-301
17. Heck PM, Hoole SP, Khan SN, Dutka DP (2010) Hyperinsulinemia improves ischemic LV function in insulin resistant subjects. Cardiovasc Diabetol 9:27
18. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
19. Pellerin D, Sharma R, Elliott P, Veyrat C (2003) Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart 89(Suppl 3):iii9-iii17
20. Madler CF, Payne N, Wilkenshoff U, Cohen A, Derumeaux GA, Pierard LA et al (2003) Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: optimal diagnostic models using off-line tissue Doppler in the MYDISE study. Eur Heart J 24:1584-1594
21. Voigt JU, Exner B, Schmiedehausen K, Huchzermeyer C, Reulbach U, Nixdorff U et al (2003) Strain-rate imaging during dobutamine stress echocardiography provides objective evidence of inducible ischemia. Circulation 107:2120-2126
22. Voigt JU, Nixdorff U, Bogdan R, Exner B, Schmiedehausen K, Platsch G et al (2004) Comparison of deformation imaging and velocity imaging for detecting regional inducible ischaemia during dobutamine stress echocardiography. Eur Heart J 25:1517-1525
23. Tesfamariam B, Brown ML, Deykin D, Cohen RA (1990) Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest. 85:929-932
24. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T et al (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154
25. Shige H, Ishikawa T, Suzukawa M, Ito T, Nakajima K, Higashi K et al (1999) Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 84(1272-4):A9
26. Tesfamariam B, Cohen RA (1992) Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 262:H1915-H1919
27. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E et al (1999) Insulin: new roles for an ancient hormone. Eur J Clin Invest 29:842-852
28. Ferrannini E, Santoro D, Bonadonna R, Natali A, Parodi O, Camici PG (1993) Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol 264:E308-E315
29. Srinivasan M, Herrero P, McGill JB, Bennik J, Heere B, Lesniak D et al (2005) The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol 46:42-48
30. Abdelmoneim SS, Hagen ME, Mendrick E, Pattan V, Wong B, Norby B et al (2013) Acute hyperglycemia reduces myocardial blood flow reserve and the magnitude of reduction is associated with insulin resistance: a study in nondiabetic humans using contrast echocardiography. Heart Vessels 28:757-768
31. Nielsen R, Norrelund H, Kampmann U, Botker HE, Moller N, Wiggers H (2013) Effect of acute hyperglycemia on left ventricular contractile function in diabetic patients with and without heart failure: two randomized cross-over studies. PLoS One 8:e53247
32. Miki T, Yuda S, Kouzu H, Miura T (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18:149-166
33. Cadeddu C, Nocco S, Piano D, Deidda M, Cossu E, Baroni MG et al (2013) Early impairment of contractility reserved in patients with insulin resistance in comparison with health subjects. Cardiovasc Diabetol. 12:66
34. Cognet T, Vervueren PL, Dercle L, Bastie D, Richaud R, Berry M et al (2013) New concept of myocardial longitudinal strain reserve assessed by a dipyridamole infusion using 2D-strain echocardiography: the impact of diabetes and age, and the prognostic value. Cardiovasc Diabetol. 12:84
35. D'Andrea A, Nistri S, Castaldo F, Galderisi M, Mele D, Agricola E et al (2012) Working group nucleus on echocardiography of Italian society of cardiology. Int J Cardiol 154:250-255
36. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT et al (2006) Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317:1106-1113
37. Zhao TC (2013) Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol. 12:90
38. Clarke SJ, McCormick LM, Dutka DP (2014) Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol. 13:12
39. McCormick LM, Kydd AC, Dutka DP (2012) Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies? Cardiovasc Hematol Agents Med Chem. 10:319-324
40. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955-961
41. Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR et al (2011) Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 6:e23570
42. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G et al (2003) Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24:569-578
43. Liedtke AJ (1981) Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 23:321-336